A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
NCT07365319 · TeLuRide-008 Phase 2/3Recruiting
- Lead sponsor
- Eikon Therapeutics (Industry)
- Enrollment
- 750 (estimated)
- Start date
- 15 Jun 2026
- Primary completion
- 31 Dec 2035 (estimated)
- Study completion
- 31 Dec 2040
- Last update posted
- 20 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 3
Interventions
- EIK1001 Drug
- Pembrolizumab (KEYTRUDA®) Drug
- Placebo Drug
- Paclitaxel + Carboplatin Drug
- Nab-paclitaxel + Carboplatin Drug
- Pemetrexed + Cisplatin /Carboplatin Drug
Conditions and primary outcome
- Non Small Cell Lung Cancer (Squamous or Non Squamous)
- Stage 4 NSCLC
Primary outcome
Progression-free survival (PFS) (Through study completion, up to 6 years); Overall survival (OS) (Through study completion, up to 10 years); Objective Response (OR) (Through study completion, up to 6 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07365319.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07365319 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.